Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bretylium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | THPO | P40225 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bretylium SCHEMBL29387750 | 1.00 | LMNA (0.63) | LMNACYP2D6CYP3A4MAPK1THPO | |
| Bretylium SCHEMBL15438 | 0.98 | LMNA (0.65) | LMNACYP2D6CYP3A4MAPK1THPO | |
| Bretylium SCHEMBL29688247 | 0.98 | LMNA (0.65) | LMNACYP2D6CYP3A4MAPK1THPO | |
| Bretylium SCHEMBL542733 | 0.98 | LMNA (0.65) | LMNACYP2D6CYP3A4MAPK1THPO | |
| Bretylium SCHEMBL6227453 | 0.96 | LMNA (0.63) | LMNACYP2D6CYP3A4MAPK1THPO | |
| Bretylium SCHEMBL16398024 | 0.96 | LMNA (0.63) | LMNACYP2D6CYP3A4MAPK1THPO | |
| Bretylium SCHEMBL428588 | 0.81 | LMNA (0.50) | LMNACYP2D6CYP3A4MAPK1THPO | |
| Bromide SCHEMBL22265059 | 0.81 | CHRM2 (0.48) | LMNACYP2D6CYP3A4MAPK1THPO | |
| Bretylium SCHEMBL40898 | 0.79 | LMNA (1.00) | LMNACYP2D6CYP3A4MAPK1THPO | |
| SCHEMBL31658959 | 0.79 | CHRM2 (0.50) | LMNACYP2D6CYP3A4MAPK1THPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113164687-B | Method of inserting a lubricant-free stopper into a lubricant-free syringe and assembly system | W.L.戈尔及同仁股份有限公司 | 2023-02-17 | — | — | CN | disclosed |
| CN-112657020-B | Syringe plunger assembly | W.L.戈尔及同仁股份有限公司 | 2022-09-27 | — | — | CN | disclosed |
| CN-114414583-A | System and method for detecting syringe seal defects | W.L.戈尔及同仁股份有限公司 | 2022-04-29 | — | — | CN | disclosed |
| CN-113164687-A | Method of inserting a lubricant-free stopper into a lubricant-free syringe or lubricant-free cartridge tube and system for assembling same | W.L.戈尔及同仁股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-112657020-A | Syringe plunger assembly | W.L.戈尔及同仁股份有限公司 | 2021-04-16 | — | — | CN | disclosed |
| CN-108472455-B | Syringe plunger assembly | W.L.戈尔及同仁股份有限公司 | 2021-01-08 | — | — | CN | disclosed |
| US-6884792-B2 | Bretylium compositions and kits and their use in preventing and treating cardiovascular conditions | BACANER MARVIN B (US) | 2005-04-26 | — | — | US | disclosed |
| US-20030119794-A1 | Novel bretylium compositions and kits and their use in preventing and treating cardiovascular conditions | BACANER MARVIN B (US) | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119794-A1 | Novel bretylium compositions and kits and their use in preventing and treating cardiovascular conditions | TNNT2, TNNI3, FABP3 | LMNA 832/4885CYP2D6 3889/4885CYP3A4 2620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.